NCT06705530 2026-02-09
A Study to Evaluate the Tolerability, Safety, and Efficacy of an Anti-CD19 CAR-T Product in Patients With B-cell Lymphoproliferative Disorders
National Research Center for Hematology, Russia
Phase 1/2 Completed
National Research Center for Hematology, Russia
Canadian Cancer Trials Group